{"nctId":"NCT01360021","briefTitle":"New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","startDateStruct":{"date":"2011-11"},"conditions":["Asthma"],"count":214,"armGroups":[{"label":"1 Symbicort/inhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Symbicort"]},{"label":"Symbicort/inhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Symbicort"]},{"label":"Budesonide/inhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Budesonide"]}],"interventions":[{"name":"Symbicort","otherNames":[]},{"name":"Symbicort","otherNames":[]},{"name":"Budesonide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female 12 years and above\n* Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months\n* Pre-bronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal\n* Patients with reversible airway obstruction\n* Documented daily use of inhaled corticosteroids for ≥ 3 months\n\nExclusion Criteria:\n\n* History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2\n* Hospitalized during previous 6 months for asthma\n* Required emergency treatment more than once during previous 6 months for an asthma-related condition\n* Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment\n* Respiratory infection affecting the asthma within 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second (FEV1) - Post Dose","description":"Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"31.46"},{"groupId":"OG001","value":"1.97","spread":"27.16"},{"groupId":"OG002","value":"2.12","spread":"26.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"32.14"},{"groupId":"OG001","value":"2.35","spread":"25.97"},{"groupId":"OG002","value":"2.28","spread":"27.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"31.98"},{"groupId":"OG001","value":"2.34","spread":"26.31"},{"groupId":"OG002","value":"2.30","spread":"30.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"32.17"},{"groupId":"OG001","value":"2.35","spread":"27.22"},{"groupId":"OG002","value":"2.33","spread":"29.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"30.71"},{"groupId":"OG001","value":"2.39","spread":"27.31"},{"groupId":"OG002","value":"2.30","spread":"28.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"30.57"},{"groupId":"OG001","value":"2.37","spread":"26.33"},{"groupId":"OG002","value":"2.30","spread":"28.36"}]}]}]},{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose","description":"Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"31.46"},{"groupId":"OG001","value":"1.97","spread":"27.16"},{"groupId":"OG002","value":"2.12","spread":"26.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"32.79"},{"groupId":"OG001","value":"2.12","spread":"28.29"},{"groupId":"OG002","value":"2.22","spread":"31.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"32.86"},{"groupId":"OG001","value":"2.11","spread":"29.96"},{"groupId":"OG002","value":"2.25","spread":"29.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"30.84"},{"groupId":"OG001","value":"2.17","spread":"31.29"},{"groupId":"OG002","value":"2.23","spread":"30.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"30.15"},{"groupId":"OG001","value":"2.15","spread":"29.15"},{"groupId":"OG002","value":"2.23","spread":"29.36"}]}]}]},{"type":"SECONDARY","title":"Peak Expiratory Flow","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"357.95","spread":"100.59"},{"groupId":"OG001","value":"335.70","spread":"102.99"},{"groupId":"OG002","value":"360.46","spread":"103.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"364.61","spread":"103.62"},{"groupId":"OG001","value":"347.86","spread":"110.80"},{"groupId":"OG002","value":"367.64","spread":"102.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379.96","spread":"104.72"},{"groupId":"OG001","value":"362.99","spread":"112.63"},{"groupId":"OG002","value":"348.94","spread":"97.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"376.28","spread":"106.76"},{"groupId":"OG001","value":"353.69","spread":"108.72"},{"groupId":"OG002","value":"343.59","spread":"98.12"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptoms Score (Total)","description":"The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"0.98"},{"groupId":"OG001","value":"1.92","spread":"0.72"},{"groupId":"OG002","value":"2.12","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"1.10"},{"groupId":"OG001","value":"1.45","spread":"0.91"},{"groupId":"OG002","value":"2.02","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)","description":"The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.54","spread":"28.97"},{"groupId":"OG001","value":"78.76","spread":"29.76"},{"groupId":"OG002","value":"81.59","spread":"25.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.73","spread":"30.90"},{"groupId":"OG001","value":"89.93","spread":"21.40"},{"groupId":"OG002","value":"84.62","spread":"26.31"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)","description":"Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"2.48"},{"groupId":"OG001","value":"2.19","spread":"1.75"},{"groupId":"OG002","value":"2.65","spread":"2.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"2.67"},{"groupId":"OG001","value":"1.26","spread":"1.60"},{"groupId":"OG002","value":"2.34","spread":"2.38"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["VIRAL UPPER RESPIRATORY TRACT INFECTION"]}}}